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Seasonal influenza (flu) causes 9.3 million to 
49.0 million illnesses and 12,000 to 79,000 
deaths in the United States annually.1 To 
combat its impact, the Centers for Disease 
Control and Prevention (CDC) recommends 
all healthy children and adults obtain a flu 
vaccination every year. In 2017-18, 57.9% of 
healthy children (6 months to 17 years old) 
obtained the vaccine, and approximately 
80% of pediatric deaths from influenza 
during that season were children who were 
unvaccinated.2 Vaccinations have been 
proven to reduce flu-related hospitalizations 
and severe illness outcomes.3,4 
 One challenge to flu vaccinations is that 
a new flu vaccine is usually created each 
year. The flu virus is constantly evolving 
and changing.5 The genetic material of 
the viruses is encoded in RNA, an unstable 
molecule that is characterized by frequent 
mutations, or random changes to the 
genome. Because of these genetic changes, 
the vaccine must be updated almost 
every flu season.5,6 Predicting the most 
dominant flu virus strains that will affect 
people each flu season is a difficult process, 
as demonstrated by the variability in the 
effectiveness of flu vaccines (Figure 1). 
 The majority of flu vaccines are created 
from three types of deactivated flu viruses: 
A(H3N2), A(H1N1), and B. The A(H3N2) virus 
is usually the most dominant and causes the 
majority of patient illness and death each 
flu season because it tends to mutate more 
frequently than the other types.7 Over the 
past decade, the A(H3N2) vaccine reduced 
the risk of having to go to the doctor with 
the flu by 25% (Figure 1).8 
 To develop a vaccine in time for 
the beginning of flu season in the fall, 
scientists must start in early January. The 
current method that the CDC uses involves 
scientists vaccinating ferrets with several 
vaccine candidates. They then extract the 
antibodies from the ferrets to estimate 
which vaccine was the most effective 
against the dominant viruses from the 
previous flu season. This method has been 
used for almost 50 years. However, it has 
been proven to be inconsistent in predicting 
how well the vaccines would perform in 
humans, especially with the recent, rapidly 
mutating A(H3N2) viruses.7-9 Additionally, 
experiments with ferrets are time-
consuming and costly.
 In contrast, mathematical models, 
including a model developed at Rice 
University over 15 years ago, allow scientists 
to calculate how well the flu vaccine 
matches the infecting viruses.10,11 The Rice 
model, called pEpitope, estimates vaccine 
effectiveness, and it has been shown to 
work well for flu A(H3N2), A(H1N1), and B 
vaccines.8,12,13 For the 2018-19 flu season, 
Rice scientists predict that the vaccine will 
be between 20–40% effective against the 
majority of A(H3N2) viruses. Unfortunately, 
the model also predicts no protection 
against a small, newly evolving group of 
A(H3N2) flu strains. Modeling, if used during 
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sure that the vaccine virus does not mutate 
during the manufacturing process. The 
pEpitope model is also low-cost, as it does 
not require any specialized equipment. 
Finally, it is extremely quick, taking 
just a couple of seconds to analyze the 
potential effectiveness of a vaccine against 
thousands of infecting viruses in a particular 
geographic region.
 The CDC should strengthen their 
current protocols for choosing vaccine 
candidates by utilizing all available 
prediction modeling. This will improve 
overall flu vaccine effectiveness rates and 
potentially coverage rates as well. Scientists 
hope that with improved effectiveness, 
they will also be able to improve vaccine 
coverage rates, which still trail behind the 
CDC’s Healthy People 2020 goal of 70%.14 
Given the difficulty in producing effective 
vaccines and the general climate of public 
mistrust of immunization, this work has 
the potential to improve vaccine strain 
selection and education by providing a tool 
that is accessible to researchers and citizen 
scientists alike.
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RECOMMENDATIONS
Public health researchers are often slow 
to change. Despite the fact that Rice’s 
pEpitope model has been around for 
more than 15 years, it is unclear why the 
CDC has yet to take advantage of it in 
developing their seasonal flu vaccine.10, 11 
 Adding such a model to the already 
existing ferret experiments will enhance 
the current vaccination decision-making 
process. This mathematical modeling 
technique can rapidly narrow down the 
viruses that would be good candidates 
for the vaccine during a particular flu 
season. It can serve as a check to make 
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